prednisolone has been researched along with Lymphangioleiomyomatosis in 2 studies
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.
Lymphangioleiomyomatosis: A disease characterized by the progressive invasion of SMOOTH MUSCLE CELLS into the LYMPHATIC VESSELS, and the BLOOD VESSELS. The majority of the cases occur in the LUNGS of women of child-bearing age, eventually blocking the flow of air, blood, and lymph. The common symptom is shortness of breath (DYSPNEA).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with lymphangioleiomyomatosis (LAM) and lung transplantations are treated with multiple drugs, such as tacrolimus, mycophenolate mofetil, prednisolone, and itraconazole, for long-term suppression of rejection response and prevention of infection." | 8.31 | Therapeutic Drug Monitoring of Blood Sirolimus and Tacrolimus Concentrations for Polypharmacy Management in a Lymphangioleiomyomatosis Patient Taking Two Cytochrome P450 3A Inhibitors. ( Hayashi, N; Hirama, T; Kikuchi, M; Kumondai, M; Maekawa, M; Mano, N; Mizuguchi, A; Okada, Y; Sato, T; Sato, Y; Ui, M, 2023) |
| "Patients with lymphangioleiomyomatosis (LAM) and lung transplantations are treated with multiple drugs, such as tacrolimus, mycophenolate mofetil, prednisolone, and itraconazole, for long-term suppression of rejection response and prevention of infection." | 4.31 | Therapeutic Drug Monitoring of Blood Sirolimus and Tacrolimus Concentrations for Polypharmacy Management in a Lymphangioleiomyomatosis Patient Taking Two Cytochrome P450 3A Inhibitors. ( Hayashi, N; Hirama, T; Kikuchi, M; Kumondai, M; Maekawa, M; Mano, N; Mizuguchi, A; Okada, Y; Sato, T; Sato, Y; Ui, M, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kumondai, M | 1 |
| Kikuchi, M | 1 |
| Mizuguchi, A | 1 |
| Hayashi, N | 1 |
| Ui, M | 1 |
| Hirama, T | 1 |
| Okada, Y | 1 |
| Sato, Y | 1 |
| Sato, T | 1 |
| Maekawa, M | 1 |
| Mano, N | 1 |
| Ovcharenko, SI | 1 |
| Osadchiĭ, KK | 1 |
| Petukhova, NV | 1 |
| Kogan, EA | 1 |
| Ablitsov, IuA | 1 |
| Koroleva, IM | 1 |
2 other studies available for prednisolone and Lymphangioleiomyomatosis
| Article | Year |
|---|---|
Therapeutic Drug Monitoring of Blood Sirolimus and Tacrolimus Concentrations for Polypharmacy Management in a Lymphangioleiomyomatosis Patient Taking Two Cytochrome P450 3A Inhibitors.
Topics: Clarithromycin; Cytochrome P-450 CYP3A; Drug Monitoring; Female; Humans; Immunosuppressive Agents; I | 2023 |
[Clinical observation of lymphangioleiomyomatosis of the lungs].
Topics: Biopsy; Budesonide; Diagnosis, Differential; Female; Humans; Lung; Lymphangioleiomyomatosis; Middle | 2004 |